Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial.

Abstract

BACKGROUND There are no data from prospective studies focused exclusively on patients with advanced lung and thymic carcinoids. We aimed to assess the efficacy and safety of long-acting pasireotide and everolimus, administered alone or in combination, in patients with advanced carcinoids of the lung or thymus. METHODS LUNA was a prospective, multicentre… (More)
DOI: 10.1016/S1470-2045(17)30681-2

Topics

Cite this paper

@article{Ferolla2017EfficacyAS, title={Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial.}, author={Piero Ferolla and Maria Pia Brizzi and Tim Meyer and Wasat Mansoor and Julien Mazi{\`e}res and Christine Do Cao and Herv{\'e} L{\'e}na and Alfredo Berruti and Vincenzo Damiano and Wieneke A Buikhuisen and Henning Gr\onb{\ae}k and C Lombard-bohas and Christian Groh{\'e} and Vincenzo Minotti and Marcello Tiseo and Javier de Castro and Nicholas Reed and Gabriella Gislimberti and Neha Singh and Miona Stankovic and Kjell {\"O}berg and Eric Baudin}, journal={The Lancet. Oncology}, year={2017}, volume={18 12}, pages={1652-1664} }